N Collongues1, D Brassat2, E Maillart3, P Labauge4, J C Ouallet5, C Carra-Dalliere4, T Moreau6, B Bourre7, C Papeix3, B Brochet5, B Audoin8, S Vukusic9, J de Seze10, R Marignier9. 1. Department of Neurology, Hopital de Hautepierre, France nicolas.collongues@chru-Strasbourg.fr. 2. Department of Neurology, Hopital Purpan, France. 3. Department of Neurology, Hopital Pitie-Salpetriere, France. 4. Department of Neurology, Hopital Universitaire de Montpellier, France. 5. Department of Neurology, Centre Hospitalier Universitaire de Bordeaux, France. 6. Department of Neurology, Hopital Universitaire de Dijon, France. 7. Department of Neurology, Hopital Charles Nicolle, France. 8. Department of Neurology, Hopital Universitaire de Marseille, France. 9. Department of neurology, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, France. 10. Department of Neurology, Hopital de Hautepierre, France.
Abstract
BACKGROUND: Despite a growing use of rituximab (RTX) in neuromyelitis optica (NMO), data are lacking in patients with refractory NMO (RNMO), defined as cases with at least one relapse during immunosuppressive therapy. OBJECTIVE: The purpose of this study was to assess RTX as a maintenance therapy in RNMO. METHODS: Out of a total of 305 NMO cases from a population-based cohort, 21 RNMO patients received RTX during a mean follow-up period of 31 months. RESULTS: After RTX, 11 patients (52.3%) were relapse free, meaning that 47.7% were refractory to RTX. The mean annualized relapse rate decreased from 1.3 to 0.4 (p<0.001) and median EDSS from 5 to 3 (p=0.02). Body mass index (BMI) was predictive of EDSS worsening. CONCLUSIONS: RTX is an effective and well-tolerated treatment in RNMO. BMI could be a predictive factor for efficacy.
BACKGROUND: Despite a growing use of rituximab (RTX) in neuromyelitis optica (NMO), data are lacking in patients with refractory NMO (RNMO), defined as cases with at least one relapse during immunosuppressive therapy. OBJECTIVE: The purpose of this study was to assess RTX as a maintenance therapy in RNMO. METHODS: Out of a total of 305 NMO cases from a population-based cohort, 21 RNMO patients received RTX during a mean follow-up period of 31 months. RESULTS: After RTX, 11 patients (52.3%) were relapse free, meaning that 47.7% were refractory to RTX. The mean annualized relapse rate decreased from 1.3 to 0.4 (p<0.001) and median EDSS from 5 to 3 (p=0.02). Body mass index (BMI) was predictive of EDSS worsening. CONCLUSIONS:RTX is an effective and well-tolerated treatment in RNMO. BMI could be a predictive factor for efficacy.
Authors: Philippe Cabre; M Mejdoubi; S Jeannin; H Merle; Y Plumelle; G Cavillon; D Smadja; R Marignier Journal: J Neurol Date: 2018-02-17 Impact factor: 4.849
Authors: Pietro Annovazzi; M Capobianco; L Moiola; F Patti; J Frau; A Uccelli; D Centonze; P Perini; C Tortorella; L Prosperini; G Lus; A Fuiani; M Falcini; V Martinelli; G Comi; A Ghezzi Journal: J Neurol Date: 2016-06-10 Impact factor: 4.849
Authors: Jan-Patrick Stellmann; Markus Krumbholz; Tim Friede; Anna Gahlen; Nadja Borisow; Katrin Fischer; Kerstin Hellwig; Florence Pache; Klemens Ruprecht; Joachim Havla; Tania Kümpfel; Orhan Aktas; Hans-Peter Hartung; Marius Ringelstein; Christian Geis; Christoph Kleinschnitz; Achim Berthele; Bernhard Hemmer; Klemens Angstwurm; Kim Lea Young; Simon Schuster; Martin Stangel; Florian Lauda; Hayrettin Tumani; Christoph Mayer; Lena Zeltner; Ulf Ziemann; Ralf Andreas Linker; Matthias Schwab; Martin Marziniak; Florian Then Bergh; Ulrich Hofstadt-van Oy; Oliver Neuhaus; Uwe Zettl; Jürgen Faiss; Brigitte Wildemann; Friedemann Paul; Sven Jarius; Corinna Trebst; Ingo Kleiter Journal: J Neurol Neurosurg Psychiatry Date: 2017-06-01 Impact factor: 10.154